We report an increase in GII.17 norovirus outbreaks and sporadic infections of acute gastroenteritis in Austria, Germany, France, Ireland, the Netherlands, England and the United States during the 2023/24 season. A decrease in GII.4 coincided with GII.17 prevalence increasing to between 17% and 64% of all GII detections. Overall, 84% of the GII.17 strains clustered closely with strains first reported in Romania in 2021 and two new sub-lineages were identified. Norovirus surveillance and molecular characterisation should be prioritised this winter.
Norovirus is the leading cause of epidemic and endemic acute gastroenteritis worldwide and the most frequent cause of foodborne illness in the United States. There is no specific treatment for norovirus infections and therapeutic interventions are based on alleviating symptoms and limiting viral transmission. The immune response to norovirus is not completely understood and mechanistic studies have been hindered by lack of a robust cell culture system. In recent years, the human intestinal enteroid/human intestinal organoid system (HIE/HIO) has enabled successful human norovirus replication. Cells derived from HIE have also successfully been subjected to genetic manipulation using viral vectors as well as CRISPR/Cas9 technology, thereby allowing studies to identify antiviral signaling pathways important in controlling norovirus infection. RNA sequencing using HIE cells has been used to investigate the transcriptional landscape during norovirus infection and to identify antiviral genes important in infection. Other cell culture platforms such as the microfluidics-based gut-on-chip technology in combination with the HIE/HIO system also have the potential to address fundamental questions on innate immunity to human norovirus. In this review, we highlight the recent advances in understanding the innate immune response to human norovirus infections in the HIE system, including the application of advanced molecular technologies that have become available in recent years such as the CRISPR/Cas9 and RNA sequencing, as well as the potential application of single cell transcriptomics, viral proteomics, and gut-on-a-chip technology to further elucidate innate immunity to norovirus.
26 February 2025 in The Journal of Infectious Diseases
Background: Noroviruses are the leading cause of acute gastroenteritis worldwide, with GII.4 Sydney viruses responsible for the majority of infections until 2023. Methods: To study the evolutionary dynamics of GII.4 noroviruses in the United States (2011–2023), we sequenced and analyzed 406 VP1 and 335 RNA-dependent RNA polymerase sequences submitted to CaliciNet. Results: Time-scale analysis showed that the average evolutionary rate of GII.4 strains was 5.56 × 10−3 substitutions per site per year. GII.4 Sydney viruses circulated throughout the entire study period albeit with 4 polymerase types (GII.P31, GII.P16, GII.P4 and GII.P12). From 2011–2015, GII.4 Sydney[P31] dominated followed by GII.4 Sydney[P16] from 2016–2020, and the new sub-lineage GII.4 Sydney[P16]-2020 from 2021–to present. Since 2017, we observed the emergence of 3 novel GII.4 clusters based on amino acids in VP1: GII.4 San Francisco, GII.4 Allegany, and GII.4 Wichita. GII.4 San Francisco and GII.4 Allegany had a GII.P31 RNA-dependent RNA polymerase, whereas GII.4 Wichita strains had GII.P4. GII.4 Allegany and GII.4 Wichita exhibited major amino acid substitutions in epitopes A to E, G, and H, while GII.4 San Francisco viruses have an alanine insertion in epitope A. GII.4 Allegany and GII.4 Wichita virus-like particles bound porcine gastric mucin at a similar level as GII.4 New Orleans and GII.4 Sydney. However, blocking of binding to virus-like particles by human serum pools demonstrated that their antigenicity was significantly different. Conclusions: We identified 3 new GII.4 noroviruses cocirculating with GII.4 Sydney. Early detection of new strains will aid in tracking their spread and assessing their pandemic potential.
2 May 2025 in Journal of Infection and Public Health
Human adenovirus (HAdV), especially HAdV species F (HAdV-F) is recognized as a cause of acute gastroenteritis (AGE) worldwide. To assess the global prevalence of HAdV in case-patients of all ages with AGE, we conducted a systematic literature search for studies published in English during 2015-2022. We generated pooled prevalence estimates using generalized linear mixed models. Using data from 147 included articles, the overall pooled prevalence among AGE case-patients of any species of HAdV (pan-HAdV) was 5.8 % and 6.0 % for HAdV-F. The prevalence of HAdV was significantly higher among case-patients < 5 years of age compared with case-patients ≥ 5 years of age (pan-HAdV: 6.6 % vs. 2.0 %, p < 0.0001; HAdV-F: 8.7 % vs. 2.3 %, p = 0.04). Prevalence was significantly higher in high mortality developing countries and lowest in developed countries (pan-HAdV: 9.4 % vs. 4.0 %, p < 0.0001; HAdV-F: 11.6 % vs. 3.2 %, p = 0.0003). Understanding the burden of HAdV-associated AGE may be useful for targeted interventions, including future vaccine development.
Norovirus is the leading cause of acute gastroenteritis worldwide. Since the development of human intestinal enteroid (HIE) cell culture systems, significant advancements have been made in exploring and evaluating therapeutic strategies to combat human norovirus infections. Here, we investigate whether 25-hydroxycholesterol (25-HC), a key regulator of cholesterol homeostasis and bile acid production, can restrict human norovirus replication in jejunal HIE monolayers. Jejunal HIE monolayers derived from two donors (J2 and J3 cell lines) were treated with increasing concentrations of 25-HC (ranging from 0.0001 µM to 5 µM) for 24 hours. Monolayers were then infected with norovirus GII.1[P33] or GII.4 Sydney[P31] and incubated for 24 hours at 37°C and 5% CO 2 . Viral RNA was quantified by reverse transcription-quantitative PCR at 1 hour post-infection (hpi) and 24 hpi. Regardless of HIE cell line or norovirus genotype, a dose-dependent restriction of human norovirus replication was observed after 25-HC treatment (0.07–1.23 log decrease). The top upregulated pathways associated with the 25-HC treatment included innate immunity and pro-inflammatory pathways, while the top downregulated pathways included cholesterol biosynthesis pathways. The 25-HC resulted in upregulation of genes associated with innate immune response, including C-C motif chemokine 2 (CCL2), CCL20, intercellular adhesion molecule 1 (ICAM1), and interleukin 23A (IL23A), and downregulation of genes related to cholesterol biosynthesis, including proprotein convertase subtilisin/kexin type 9 and acetyl-CoA acetyltransferase (ACAT2). Our data suggest that modulating the downstream signaling pathway of 25-HC has therapeutic potential as a strategy to control human norovirus infections and enhance antiviral immune responses. IMPORTANCE: Human noroviruses are a leading cause of both epidemic and endemic acute gastroenteritis worldwide. Currently, there are no licensed vaccines or antiviral treatments available. The immune response to human norovirus infection remains incompletely understood. The development of the human intestinal enteroid (HIE) system has revolutionized norovirus research by enabling detailed investigations into viral replication, evaluation of potential control strategies, and analysis of host cellular responses involving both innate and adaptive immunity. In recent years, 25-hydroxycholesterol (25-HC) has emerged as a key regulator of cellular metabolism and antiviral defense. In this study, we investigated the antiviral effects of 25-HC on human norovirus using the HIE culture system. Our findings highlight the therapeutic potential of 25-HC in controlling human norovirus infections and enhancing antiviral immune responses, thereby contributing to a deeper understanding of host restriction mechanisms in viral infections.
GII.4 noroviruses have been the leading cause of acute gastroenteritis outbreaks in the United States (U.S.) for the past decade. Recently, GII.17 viruses have emerged globally, raising concerns about changes in disease burden and potential replacement of GII.4 as the predominant strain. We characterized molecular and epidemiological features of U.S. GII.17 norovirus outbreaks from September 2021-August 2025 submitted to CaliciNet. Norovirus-positive outbreak samples were sequenced followed by RdRp and VP1 phylogenetic analyses. CaliciNet and National Outbreak Reporting System data were linked to compare GII.17 and GII.4 epidemiologic and clinical characteristics. Virus-like particles binding to gastric mucin and antibody blockade assays were conducted to assess antigenic variation among GII.17 variants. Among 1,412 outbreaks, GII.17 prevalence increased from 5.0% (2021-2022) to 74.8% (2024-2025). Compared with GII.4, GII.17 was more frequently reported with foodborne exposure (16.4% vs 9.6%), affected persons aged 10-49 years compared with other groups (31.1% vs 23.1%), and associated with slightly higher rates of vomiting (78.2% vs 72.2%), abdominal cramps (34.2% vs 30.1%), and fever (15.9% vs 10.9%). Phylogenetic analysis detected GII.17[P17] Romania-like (93.3%) followed by GII.17[P17] Kawasaki308-like strains (4.6%) and two novel tentative variants: Santa Clara (1.3%) and London (0.1%). Despite substitutions in key P2 antigenic sites, surrogate antibody neutralization remained conserved. These findings indicate a recent shift in norovirus genotype dominance in the U.S., likely driven by enhanced transmissibility or population susceptibility rather than increased virulence. Continued molecular surveillance is essential to monitor viral evolution and public health impact of norovirus.